Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
FEBS Lett. 2012 Jun 4;586(11):1562-9. doi: 10.1016/j.febslet.2012.04.032. Epub 2012 Apr 25.
The von Hippel-Lindau tumor suppressor gene (VHL) is best known as an E3 ubiquitin ligase that negatively regulates the hypoxia inducible factor (HIF). VHL mutations are the genetic defects underlying several human diseases including polycythemia, familial VHL tumor syndrome and sporadic renal cell carcinoma. VHL mutations can lead to cell-autonomous phenotypes in the tumor cells. However, non-tumor cell-autonomous functions of VHL have also been noted. VHL tumor-derived cytokines can promote inflammation and induce mobilization of endothelial progenitor cells. Up-regulation of HIF caused by VHL loss-of-function mutants, including heterozygotes, has been shown to increase the activities of hematopoietic stem cells, endothelial cells and myeloid cells. As such, systemic functions of VHL likely play important roles in the development of VHL disease.
希佩尔-林道肿瘤抑制基因(VHL)作为一种 E3 泛素连接酶而闻名,其可负向调节缺氧诱导因子(HIF)。VHL 基因突变是多种人类疾病的遗传缺陷,包括红细胞增多症、家族性 VHL 肿瘤综合征和散发性肾细胞癌。VHL 基因突变可导致肿瘤细胞中的自主表型。然而,也已经注意到 VHL 的非肿瘤细胞自主功能。VHL 肿瘤衍生的细胞因子可促进炎症并诱导内皮祖细胞的动员。VHL 失活突变体(包括杂合子)引起的 HIF 上调已被证明可增加造血干细胞、内皮细胞和髓样细胞的活性。因此,VHL 的全身功能可能在 VHL 疾病的发展中发挥重要作用。